Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus
Journal of Microbiology and Biotechnology · 2025
DOI: 10.4014/jmb.2509.09047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2025. Verfasst von Taehyun Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Influenza A Virus, H1N1 Subtype, Antibodies, Neutralizing, Orthomyxoviridae Infections. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of SMEs and Startups.
Abstract (Originalsprache)
Influenza viruses remain a persistent threat to both human and animal health, whereas current countermeasures-vaccination and livestock culling-offer only delayed, partial, or economically burdensome protection. Here, we describe the development of a mucosal nanotherapy based on chromosome-free minicells derived from Lactiplantibacillus plantarum, engineered to surface-display a broadly reactive anti-hemagglutinin nanobody. These therapeutic agents, termed "neutralizing nanosomes" present nanobody molecules anchored on the minicell surface that retain full binding functionality against a broad spectrum of influenza viruses, including H1N1. Importantly, intranasal administration of neutralizing nanosomes effectively neutralized H1N1 infection in vivo, alleviating physiological symptoms and suppressing viral replication in the respiratory tract of a preclinical mouse model. Unlike vaccines, which require weeks to confer protection, our neutralizing nanosomes provide an immediate barrier at the respiratory mucosa-the primary portal of influenza entry-offering a promising adjunct to existing vaccines and antiviral drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Department of Microbiology & Immunology, Seoul National University College of Medicine, Seoul 08826, Republic of Korea.
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Republic of Korea.
- Saeloun Bio Inc., Seoul 08826, Republic of Korea.
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Förderung
- Ministry of SMEs and Startups
Zitieren
APA
Kim, T., Jang, I. H., Shin, S., Kang, J., Ahn, H. J., Moon, S., Kim, J., Ryu, J. H., & Lee, K. A. (2025). Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2509.09047
Vancouver
Kim T, Jang IH, Shin S, Kang J, Ahn HJ, Moon S, et al. Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus. Journal of Microbiology and Biotechnology. 2025. doi:10.4014/jmb.2509.09047
BibTeX
@article{Kim2025,
author = {Kim, Taehyun and Jang, In-Hwan and Shin, Sohyeon and Kang, Juhyun and Ahn, Hyo-Joo and Moon, Sungmin and Kim, Juhyun and Ryu, Ji-Hwan and Lee, Kyung-Ah},
title = {Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
doi = {10.4014/jmb.2509.09047}
}
EUVIMED